For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.
You are here : Home > PAD Profile : Insulin pump - Type 1 diabetes - Diabetes Mellitus
PAD Profile : Insulin pump - Type 1 diabetes - Diabetes Mellitus
Traffic Light Status
Status 1 of 1.
Guidelines
The following guidelines are available for this indication.
Other Drugs
Other Indications
- Lambert-Eaton myasthenic syndrome (LEMS)
- Pain
- Osteoarthritis
- Erectile dysfunction
- Hyperuricaemia and Gout
- Dysphagia
- Low sexual desire in menopausal women
- Psoriasis
- Atopic dermatitis
- Multiple sclerosis
- Duchenne muscular dystrophy
- Multiple sclerosis
- Systemic Lupus Erythematosus
- Inclusion body myositis
- Systemic Lupus Erythematosus
- Duchenne muscular dystrophy
- Systemic Lupus Erythematosus
- Multiple sclerosis
- Short bowel syndrome
- Any paediatric use
- Erectile dysfunction combination therapy
- Children and young people with Epilepsy
- Interface Prescribing Policy (IPP)
- Restless Leg Syndrome
- Pain (Chronic)
- Narcolepsy
- All
- Atopic dermatitis
- Psoriasis
- Inflammatory bowel disease
- Ulcerative colitis - moderately to severely active
- Migraine (prevention)
- Dry eyes
- Cancer
- Diarrhoea
- Ulcerative colitis - moderately to severely active
- Non-radiographic axial spondyloarthritis
- Photoaggravated dermatoses
- Photodermatoses
- Metabolic disorders
- Insomnia in adults
- Cardiomyopathy
- Epidermolysis bullosa
- Photoaggravated dermatoses
- Psoriasis
- Psoriatic arthritis
- Photodermatoses
- Photodermatoses
- Photoaggravated dermatoses
- Catheter maintenance solutions
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dry eyes
- Dysphagia
- Prurigo nodularis
- Vitamin D deficiency and insufficiency
- Osteoporosis
- Migraine (prevention)
- Pain
- Pustular psoriasis
- Mucus clearance
- Atopic dermatitis
- Alopecia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Smoking cessation
- Pain
- Homozygous familial hypercholesterolaemia
- Asthma
- Chronic Obstructive Pulmonary Disease (COPD)
- Metabolic disorders
- Concious sedation
- Premedication
- post Bariatric surgery
Additional Documents
Committee Recommendations
The National Institute for Health and Care Excellence (NICE) Technology Appraisal (TA) for Hybrid Closed Loop (HCL) Systems used in Type I diabetes was published in December 2023 and local healthcare systems are mandated to ensure that the recommendations made are followed within the NICE implementation timeframes. Unusually for NICE, a 5-year implementation strategy has been agreed based on a request from NHS England.
NICE state that:
‘HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England and implemented following NHS England's implementation plan’.
NHS England have recently issued implementation guidance and each Integrated Care Board is asked to set out how they will implement the NICE guidance, taking into account the capacity at local trusts to provide specialist support for access to HCLs.
The Surrey Heartlands Integrated Care System Area Prescribing Committee agreed a proposed phased approach as recommended by NHS England, at their meeting on 7th March 2024. As soon as information on which HCLs are cost effective, is provided by NHS England, Surrey Heartlands will move to a phased implementation.
This will take time as the local specialist teams provide some baseline data and a financial impact assessment is undertaken.
Surrey Heartlands leads are aware of interest from the diabetes community for the long-awaited NICE TA and are working with specialists to ensure all the recommended HCLs are made available, for appropriate patients as the phased implementation moves forward.
Patients are advised to liaise with their diabetes team about which insulin pumps and continuous glucose monitoring systems are suitable for them whilst this guidance is implemented.
Availability of Omnipod 5 Hybrid Closed Loop (HCL) Insulin Pump for Surrey Heartlands patients living with Type I diabetes.
The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed that they will not make any decision about Omnipod 5 availability until National Guidance is published (expected December 2023).
Please see the statement attached below from the APC for further information
The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed that the following insulin pumps will be available in line with NICE TA151 for patients with Type I Diabetes.
- Medtronic 780g insulin Pump (Medtronic)
- T-Slim insulin Pump (Air Liquide Healthcare Ltd)
- Ypsopump insulin pump (Ypsomed Ltd)
- Omnipod DASH patch pump (Insulet International Ltd)
- Dana I (Advanced Therapeutics (UK) Ltd) – replaces Dana RS insulin pump (upgrade)
- GlucoMen® Day Insulin Patch Pump (A. Menarini Diagnostics)
- A8 TouchCare Nano (Medtrum Ltd)
A RED traffic light status for the insulin pumps and the consumables is agreed by APC.
Trusts should work with their procurement leads to sign up to the NHS Supplies framework so that national agreed discounts and associated savings can be realised.